



# Unlocking the Potential of Cannabinoid Medicines

<b>Exchange:</b>	TSX: IN	OTCQX: IMLFF
<b>Share Price (04/11/19):</b>	C\$0.50	\$0.37
<b>Market Capitalization (04/11/19):</b>	C\$85.2M	\$62.9M

## Company Highlights

InMed is a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs.

Explores the potential of all 100+ cannabinoid compounds, not just THC & CBD	Selects specific cannabinoids (or combinations thereof) with potential to play a role in regulating specific diseases	Biosynthesizes cannabinoids that are biologically identical to those produced by the plant	Develops innovative, topically applied therapies for diseases with high unmet medical need
--	---	--	--

## Cannabinoids

Beyond the two most well-known cannabinoids THC and CBD, the human body's endocannabinoid receptors are predisposed to interact with more than 100 other cannabinoids that have potential therapeutic properties. Many of these cannabinoids have been neglected as targets of scientific research because they are found in extremely low concentrations in the cannabis plant.

InMed is developing novel, non-THC, topically applied cannabinoid-based treatments of diseases with high unmet medical needs.

## Biosynthesis


Proprietary biosynthesis program will allow InMed, and potentially other companies, through commercial partnerships, to access cannabinoids that are found in very limited amounts in the plant. These cannabinoids (i.e. "minor cannabinoids") may hold significant potential to treat human diseases.

This potentially industry-disruptive cannabinoid manufacturing process may offer several advantages over traditional methods (extraction from plants and chemical synthesis), which include:

Of the extensive spectrum of potential diseases, InMed's initial two target indications address total market opportunities of

**>\$6.6B**

**\$1B**  
**POTENTIAL MARKET**  
**\$5.6B**



Significant cost & time savings vs existing growing / harvesting / extraction / purification methods

Access to minor cannabinoids that are currently economically unfeasible via plant extraction

Enhanced production, purification and quality control vs naturally-sourced products

Increased structural integrity vs chemical manufacturing methods

## Clinical Pipeline

	INM-755	INM-085	INM-405
<b>Therapeutic Area</b>	Epidermolysis Bullosa	Glaucoma	Orofacial Pain
<b>Addressable Market</b>	10.1K	14.2M	52.7M
<b>Market Potential</b>	\$1.0B	\$5.6B	\$4.0B

## Strong Intellectual Property Strategy

Filed several **Patent Cooperation Treaty (PCT) and provisional patent applications** to protect our inventions. Recent **PCT patent applications** include:

**Mar. 18, 2019:** Biosynthesis technology for the manufacturing of pharmaceutical-grade cannabinoids

**Sept. 25, 2018:** INM-405 program and other unique compositions as cannabinoid-based topical therapies for the treatment of pain

**Sept. 10, 2018:** Proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature

**May 14, 2018:** INM-085, a cannabinoid-based topical therapy for glaucoma

**May 4, 2017:** Cannabinoid-based topical therapy for diseases and conditions associated with Intermediate Filament Dysfunction

**Mar. 2, 2017:** INM-755 as a cannabinoid-based topical therapy for EB Simplex

### INM-755 Epidermolysis Bullosa (“EB”)

- Group of genetic conditions causing skin to be very fragile and blister / rupture easily in response to minor injury or friction, such as rubbing or scratching
- INM-755 being investigated to deliver symptomatic relief in all EB patients via multiple potential mechanisms:
  - ✓ accelerated wound healing
  - ✓ pain reduction
  - ✓ itch reduction
  - ✓ reduce inflammation
  - ✓ antimicrobial activity
- May re-establish the epidermal / dermal junction by upregulation of specific keratins in the skin, potentially reversing the disease in a subset of EB patients



### INM-085 Glaucoma

#### Dual Mechanism of Action

- ✓ Reduces the intraocular pressure (IOP) in the affected eyes
- ✓ Provide neuroprotection for the retinal ganglion cells (RGCs) and other optic nerve tissues in the affected eyes

#### Proprietary Delivery System

- ✓ INM-085 utilizes a 1x per day hydrogel to improve compliance
- ✓ Preclinical animal data showed enhanced penetration of cannabinoid molecules through the cornea and lens compared to control



## Recent News

### Mar. 18, 2019

- ✓ Published the first in a series of pending patent applications directed to biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids

### Mar. 13, 2019

- ✓ Transitioned to single cannabinoid investigational drug candidate – INM 755 – for its EB program

### Mar. 6, 2019

- ✓ Appointed Dr. Steven M. Dinh to Scientific Advisory Board

### Dec. 4, 2018

- ✓ Received funding from the Government of Canada to support development of novel cannabinoid biosynthesis program

### Nov. 5, 2018

- ✓ Appointed Michael Woudenberg as Vice President, Chemistry, Manufacturing and Controls

## Development Timeline

- INM-755**
  - ✓ 1H19: Selected CMO for GMP production of topical cream
  - 1H19: Submit Clinical Trial Application to Health Canada
  - 2H19: Initiate Phase 1 clinical trials
- INM-085**
  - ✓ 2H18: Conducted additional *in vitro* analyses
  - 1H19: Initiate additional preclinical *in vivo* studies
  - 1H19: Conduct additional formulation optimization

## Management Team

### Eric A. Adams, MIBS Chief Executive Officer

25+ years experience in global biopharma leadership, business development, sales, marketing, M&A with enGene, QLT, Abbott, Fresenius.

### Jeff Charpentier, CPA, CA Chief Financial Officer

25+ years financial experience in biotech and tech companies, including Lifebank Corp., Inex Pharmaceuticals, and Chromos Molecular Systems.

### Josh Blacher, MBA Chief Business Officer

20+ years senior leadership, capital markets experience with Therapix, Galmed, Teva; investment banking with Morgan Stanley, and Lehman Bros.

### Alexandra D.J. Mancini, MSc SVP, Clinical and Regulatory Affairs

30+ years experience in global biopharmaceutical R&D with numerous biotech companies, including Sirius Genomics, INMEX Pharmaceuticals, and QLT.

### Dr. Eric C. Hsu, PhD VP, Preclinical R&D

18+ years scientific leadership experience with enGene Inc. in novel gene transfer technologies, formulation development and process development.

### Michael Woudenberg, P.Eng. VP, Chemistry, Manufacturing & Controls

20+ years experience in engineering, leadership and GMP manufacturing and scale up at 3M, Cardiome Pharma, Arbutus Biopharma, and Phytion Biotech.



## Investor Relations Contacts

Josh Blacher  
InMed Pharma, CBO  
(778) 945-0960  
jblacher@inmedpharma.com

Joe Green  
Edison Advisors  
(646) 653-7035  
jgreen@edisongroup.com

## Financials

TSX: IN	
Shares Outstanding	170.9M
Options/Warrants	50.5M
Fully Diluted	222.1M
Cash/Cash Equivalents on Hand (at 12/31/18)	C\$22.9M